Insider

Alcon Inc

ALC Health Care · 1 analysis

Mentioned in recent filings: Ukraine Russia Tariffs Going-concern doubt

What changed

Company history

October 2026

ALCON INC: 12 recorded developments from 5 official sources in 2026-10.

  • 2026-09-28: Attendees will have opportunities to engage with Alcon innovations through the WaterInnovations™ Immersive Experience, MARLO demonstrations and an Innovation Suite featuring Voyager™ DSLT and the Valeda® PBM device at Academy 2026. Source
  • 2026-09-28: The Innovation Suite will feature Voyager DSLT and Valeda PBM, giving optometrists an opportunity to learn about technologies supporting care for glaucoma and dry age-related macular degeneration patients. Source
  • 2026-09-28: Alcon helps more than 260 million people in over 140 countries and territories each year with eye conditions and employs more than 25,000 associates enhancing quality of life through innovative products and programs. Source
  • 2026-09-28: TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease and should not be administered while wearing contact lenses; lenses may be reinserted 15 minutes following administration. Source
  • 2026-09-28: The Voyager DSLT device is an automated ophthalmic laser device for direct selective laser trabeculoplasty that uses a Q-switched, 3-ns pulse width, frequency-doubled Nd:YAG laser at 532 nm, directs a 400-μm beam to the limbus without contact, and uses image-processing and eye-tracking a Source
  • 2026-09-29: Featured innovations include the UNITY platform, highlighted by the new UNITY M ophthalmic microscope, along with Clareon PanOptix Pro, Clareon TruPlus IOLs, Valeda Photobiomodulation (PBM) and Voyager DSLT. Source
  • 2026-09-29: Alcon's more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Source
  • 2026-09-29: In July 2026, Alcon and Aravind launched the Aravind Retina Centre of Excellence in Coimbatore, India, a dedicated training facility designed to expand retina education, facilitate knowledge exchange and provide hands-on learning opportunities for Eye Care Professionals in India and beyo Source
  • 2026-09-29: In 2024, Alcon and Aravind launched the Global Centre of Excellence for advanced cataract surgery training, helping equip surgeons with the skills and technologies needed to deliver high-quality care. Source
  • 2026-10-01: Alcon (SIX/NYSE: ALC) announced new investigator-initiated clinical data demonstrating that SYSTANE® PRO Preservative-Free (PF) provided clinically comparable dry eye symptom relief to MIEBO^ (perfluorohexyloctane ophthalmic solution), meeting the study's primary endpoint of non-inferior Source
  • 2026-10-20: Alcon acquired Neurotech Pharmaceuticals, Inc. Source
  • 2026-10-20: Alcon's acquisition of Neurotech includes ENCELTO (revakinagene taroretcel-lwey), an encapsulated cell therapy intended for surgical intravitreal implantation. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Alcon Inc ALC———
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Large funds (13F)

FundSharesValueChange in sharesQuarter
Norges Bank (Norway's sovereign fund)10,976,697$741,431,995—Q2 2026
Fidelity (FMR)7,567,130$489,960,885-1.3%Q3 2026
D. E. Shaw & Co.2,918,650$188,982,588+57.1%Q3 2026
Two Sigma Investments2,030,060$131,446,385+346.6%Q3 2026
Citadel Advisors684,878$44,345,851+73.2%Q3 2026
BlackRock638,773$41,360,589-1.8%Q3 2026
Wellington Management114,082$7,375,467+1.4%Q3 2026
Millennium Management106,204$6,876,709+470.6%Q3 2026
Bridgewater Associates28,891$2,176,937—Q1 2026
State Street6,123$396,4640.0%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.